Compare Pfizer Inc. with Similar Stocks
Dashboard
1
High Management Efficiency with a high ROCE of 16.86%
2
Strong ability to service debt as the company has a low Debt to EBITDA ratio of 2.16 times
3
The company has declared Positive results for the last 3 consecutive quarters
4
With ROCE of 12.73%, it has a very attractive valuation with a 1.99 Enterprise value to Capital Employed
5
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
USD 259,645 Million (Large Cap)
15.00
NA
281.45%
0.60
19.63%
3.00
Revenue and Profits:
Net Sales:
14,451 Million
(Quarterly Results - Mar 2026)
Net Profit:
2,709 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-4.14%
0%
-4.14%
6 Months
1.46%
0%
1.46%
1 Year
7.22%
0%
7.22%
2 Years
-10.08%
0%
-10.08%
3 Years
-34.05%
0%
-34.05%
4 Years
-50.37%
0%
-50.37%
5 Years
-35.44%
0%
-35.44%
Pfizer Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
5.60%
EBIT Growth (5y)
7.85%
EBIT to Interest (avg)
12.68
Debt to EBITDA (avg)
2.16
Net Debt to Equity (avg)
0.50
Sales to Capital Employed (avg)
0.39
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
126.85%
Pledged Shares
0
Institutional Holding
70.00%
ROCE (avg)
16.86%
ROE (avg)
21.23%
Valuation key factors
Factor
Value
P/E Ratio
15
Industry P/E
Price to Book Value
3.00
EV to EBIT
17.76
EV to EBITDA
12.91
EV to Capital Employed
2.25
EV to Sales
4.97
PEG Ratio
0.74
Dividend Yield
281.45%
ROCE (Latest)
12.69%
ROE (Latest)
19.63%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
No Trend
Mildly Bearish
Shareholding Snapshot : Mar 2026
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 243 Schemes (26.21%)
Foreign Institutions
Held by 684 Foreign Institutions (15.69%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ
Mar'26
Dec'25
Change(%)
Net Sales
14,451.00
17,557.00
-17.69%
Operating Profit (PBDIT) excl Other Income
5,864.00
5,476.00
7.09%
Interest
668.00
711.00
-6.05%
Exceptional Items
-404.00
-5,558.00
92.73%
Consolidate Net Profit
2,709.00
-1,640.00
265.18%
Operating Profit Margin (Excl OI)
294.20%
215.80%
7.84%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2026 is -17.69% vs 5.42% in Dec 2025
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2026 is 265.18% vs -146.20% in Dec 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
62,579.00
63,627.00
-1.65%
Operating Profit (PBDIT) excl Other Income
23,698.00
23,496.00
0.86%
Interest
2,671.00
3,091.00
-13.59%
Exceptional Items
-8,749.00
-8,006.00
-9.28%
Consolidate Net Profit
7,787.00
8,051.00
-3.28%
Operating Profit Margin (Excl OI)
273.40%
259.10%
1.43%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is -1.65% vs 6.84% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -3.28% vs 270.67% in Dec 2024
About Pfizer Inc. 
Pfizer Inc.
Pharmaceuticals & Biotechnology
Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology, rare diseases and consumer healthcare. EH includes legacy brands, branded generics, generic sterile injectable products, biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. Its brands include Prevnar 13, Xeljanz, Eliquis, Lipitor, Celebrex, Pristiq and Viagra.
Company Coordinates 
Company Details
235 E 42ND ST , NEW YORK NY : 10017-5703
Registrar Details






